These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 2556080)

  • 21. DNA gyrase as a drug target.
    Maxwell A
    Biochem Soc Trans; 1999 Feb; 27(2):48-53. PubMed ID: 10093705
    [No Abstract]   [Full Text] [Related]  

  • 22. Unique biological properties and molecular mechanism of 5,6-bridged quinolones.
    Macinga DR; Renick PJ; Makin KM; Ellis DH; Kreiner AA; Li M; Rupnik KJ; Kincaid EM; Wallace CD; Ledoussal B; Morris TW
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2526-37. PubMed ID: 12878515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mode of action of the new quinolones: new data.
    Hooper DC; Wolfson JS
    Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):223-31. PubMed ID: 1650698
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts.
    Hussy P; Maass G; Tümmler B; Grosse F; Schomburg U
    Antimicrob Agents Chemother; 1986 Jun; 29(6):1073-8. PubMed ID: 3015015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Inhibitory activity of NM394, the active form of prodrug prulifloxacin against type II topoisomerase from Pseudomonas aeruginosa].
    Tani M; Maebashi K; Araake M; Watabe H
    Jpn J Antibiot; 2002 Dec; 55(6):882-5. PubMed ID: 12621742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibacterial activities and inhibitory effects of sitafloxacin (DU-6859a) and its optical isomers against type II topoisomerases.
    Akasaka T; Kurosaka S; Uchida Y; Tanaka M; Sato K; Hayakawa I
    Antimicrob Agents Chemother; 1998 May; 42(5):1284-7. PubMed ID: 9593169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of active site binding of 4-quinolones and novel flavone gyrase inhibitors to DNA gyrase.
    Hilliard JJ; Krause HM; Bernstein JI; Fernandez JA; Nguyen V; Ohemeng KA; Barrett JF
    Adv Exp Med Biol; 1995; 390():59-69. PubMed ID: 8718602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones.
    Cullen ME; Wyke AW; Kuroda R; Fisher LM
    Antimicrob Agents Chemother; 1989 Jun; 33(6):886-94. PubMed ID: 2548439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis.
    Onodera Y; Tanaka M; Sato K
    J Antimicrob Chemother; 2001 Apr; 47(4):447-50. PubMed ID: 11266418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of action of the des-F(6) quinolone BMS-284756 measured by supercoiling inhibition and cleavable complex assays.
    Wu P; Lawrence LE; Denbleyker KL; Barrett JF
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3660-2. PubMed ID: 11709365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential.
    Elsea SH; McGuirk PR; Gootz TD; Moynihan M; Osheroff N
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2179-86. PubMed ID: 8257142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quinolone mode of action.
    Hooper DC
    Drugs; 1995; 49 Suppl 2():10-5. PubMed ID: 8549276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae.
    Onodera Y; Uchida Y; Tanaka M; Sato K
    J Antimicrob Chemother; 1999 Oct; 44(4):533-6. PubMed ID: 10588315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of different classes of inhibitors on DNA gyrase from Mycobacterium smegmatis.
    Chatterji M; Unniraman S; Mahadevan S; Nagaraja V
    J Antimicrob Chemother; 2001 Oct; 48(4):479-85. PubMed ID: 11581225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance.
    Fisher LM; Lawrence JM; Josty IC; Hopewell R; Margerrison EE; Cullen ME
    Am J Med; 1989 Nov; 87(5A):2S-8S. PubMed ID: 2574005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contribution of the 8-methoxy group to the activity of gatifloxacin against type II topoisomerases of Streptococcus pneumoniae.
    Kishii R; Takei M; Fukuda H; Hayashi K; Hosaka M
    Antimicrob Agents Chemother; 2003 Jan; 47(1):77-81. PubMed ID: 12499172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance.
    Hooper DC
    Clin Infect Dis; 1998 Aug; 27 Suppl 1():S54-63. PubMed ID: 9710672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cloning, expression, and enzymatic characterization of Pseudomonas aeruginosa topoisomerase IV.
    Akasaka T; Onodera Y; Tanaka M; Sato K
    Antimicrob Agents Chemother; 1999 Mar; 43(3):530-6. PubMed ID: 10049263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
    Strahilevitz J; Hooper DC
    Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones.
    Morrissey I; George JT
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():101-6. PubMed ID: 10824040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.